skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Improving cancer treatment with cyclotron produced radionuclides. Progress report

Abstract

Our goal is to improve the scientific basis for tumor diagnosis, treatment and treatment follow-up based on the use of cyclotron produced radiotracers in oncology. The grant includes 3 interactive components: Radiochemistry/Cyclotron; Pharmacology; and Immunology. The radiochemistry group seeks to develop innovative cyclotron targetry, radiopharmaceuticals, and radiolabeled antibodies, which are then used to assess important unanswered questions in tumor pharmacology and immunology. Examples include selected positron emitting radionuclides, such as Iodine-124, and Ga-66; I-124, I-123, I-131 labeled iododeoxyuridine, C-11 colchicine, and antimetabolites, like C-11 methotrexate; and radiolabeled antibodies, 3F8, M195, A33, and MRK16 for application in the pharmacology and immunology projects. The pharmacology program studies tumor resistance to chemotherapy, particularly the phenomenon of multidrug resistance and the relationship between tumor uptake and retention and the tumor response for anti-metabolite drugs. The immunology program studies the physiology of antibody localization at the tissue level as the basis for novel approaches to improving tumor localization such as through the use of an artificial lymphatic system which mechanically reduces intratumoral pressures in tumors in vivo. Quantitative imaging approaches based on PET and SPECT in radioimmunotherapy are studied to give greater insight into the physiology of tumor localization and dosimetry.

Authors:
;
Publication Date:
Research Org.:
Sloan-Kettering Inst. for Cancer Research, New York, NY (United States)
Sponsoring Org.:
USDOE, Washington, DC (United States)
OSTI Identifier:
10177525
Report Number(s):
DOE/ER/60407-6
ON: DE92040305
DOE Contract Number:
FG02-86ER60407
Resource Type:
Technical Report
Resource Relation:
Other Information: PBD: 4 Aug 1992
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; 38 RADIATION CHEMISTRY, RADIOCHEMISTRY, AND NUCLEAR CHEMISTRY; URIDINE; LABELLING; RADIOPHARMACEUTICALS; CHEMICAL PREPARATION; PROGRESS REPORT; NUCLEAR MEDICINE; RADIOCHEMISTRY; IODINE 124; GALLIUM 66; POSITRON COMPUTED TOMOGRAPHY; IMMUNOGLOBULINS; CYCLOTRONS; RADIOIMMUNOTHERAPY; PATIENTS; FLUORINE 18; 550603; 400703; EXTERNAL RADIATION IN THERAPY; RADIOISOTOPE PRODUCTION

Citation Formats

Larson, S.M., and Finn, R.D.. Improving cancer treatment with cyclotron produced radionuclides. Progress report. United States: N. p., 1992. Web. doi:10.2172/10177525.
Copy to clipboard
Larson, S.M., & Finn, R.D.. Improving cancer treatment with cyclotron produced radionuclides. Progress report. United States. doi:10.2172/10177525.
Copy to clipboard
Larson, S.M., and Finn, R.D.. Tue . "Improving cancer treatment with cyclotron produced radionuclides. Progress report". United States. doi:10.2172/10177525. https://www.osti.gov/servlets/purl/10177525.
Copy to clipboard
@article{osti_10177525,
title = {Improving cancer treatment with cyclotron produced radionuclides. Progress report},
author = {Larson, S.M. and Finn, R.D.},
abstractNote = {Our goal is to improve the scientific basis for tumor diagnosis, treatment and treatment follow-up based on the use of cyclotron produced radiotracers in oncology. The grant includes 3 interactive components: Radiochemistry/Cyclotron; Pharmacology; and Immunology. The radiochemistry group seeks to develop innovative cyclotron targetry, radiopharmaceuticals, and radiolabeled antibodies, which are then used to assess important unanswered questions in tumor pharmacology and immunology. Examples include selected positron emitting radionuclides, such as Iodine-124, and Ga-66; I-124, I-123, I-131 labeled iododeoxyuridine, C-11 colchicine, and antimetabolites, like C-11 methotrexate; and radiolabeled antibodies, 3F8, M195, A33, and MRK16 for application in the pharmacology and immunology projects. The pharmacology program studies tumor resistance to chemotherapy, particularly the phenomenon of multidrug resistance and the relationship between tumor uptake and retention and the tumor response for anti-metabolite drugs. The immunology program studies the physiology of antibody localization at the tissue level as the basis for novel approaches to improving tumor localization such as through the use of an artificial lymphatic system which mechanically reduces intratumoral pressures in tumors in vivo. Quantitative imaging approaches based on PET and SPECT in radioimmunotherapy are studied to give greater insight into the physiology of tumor localization and dosimetry.},
doi = {10.2172/10177525},
journal = {},
number = ,
volume = ,
place = {United States},
year = {Tue Aug 04 00:00:00 EDT 1992},
month = {Tue Aug 04 00:00:00 EDT 1992}
}
Copy to clipboard
Technical Report:
View Technical Report (0.98 MB)
DOI:  10.2172/10177525
Save / Share:
Export Metadata
Save to My Library
You must Sign In or Create an Account in order to save documents to your library.

  • ;
    This report describes our continuing long term goal of promoting nuclear medicine applications by improving the scientific basis for tumor diagnosis, treatment and treatment follow-up based on the use of cyclotron produced radiotracers in oncology. The program includes 3 interactive components: Radiochemistry/Cyclotron; Pharmacology; and Immunology. An essential strategy is as follows: novel radionuclides and radiotracers developed in the Radiochemistry/Cyclotron section will be employed in the Pharmacology and Immunology sections during the next year. The development of novel radionuclides and tracers is of course useful in and of itself, but their utility is greatly enhanced by the interaction with the immunologymore » and pharmacology components of the program.« less

  • This report is divided into six sections, each section dealing with a separate aspect of the program. The six sections are entitled (1) In Vivo Measurement of Amino Acid Transport and Protein Synthesis, (2) Angiogenesis in Human Gliomas: Correlations with Blood Flow and Transport of C-11 AIB, (3) Use of F-18 Fluoropyrimidines for Design and Evaluation of Regional and Systemic Chemotherapeutic Strategies in Human Adenocarcinomas of the Gastrointestinal Tract, (4) Enzymatic Synthesis of Metabolites Labeled with N-13 or C-11, (5) Synthesis of Amino Acids Labeled with C-11, and (6) Instrumentation: Cyclotron and Imaging Systems.

  • This report describes the author`s continuing long term goal of promoting nuclear medicine applications by improving the scientific basis for tumor diagnosis treatment and treatment follow-up based on the use of cyclotron produced radiotracers in oncology. The program has 3 interactive components: Radiochemistry /Cyclotron; Pharmacology; and Immunology. An essential strategy is as follows: novel radionuclides and radiotracers developed in the Radiochemistry/Cyclotron section under the DOE grant during the 1989--1992 grant period, will be employed in the Pharmacology and Immunology sections of the DOE grant during the 1992--1995 grant period. The development of novel radionuclides and tracers is of course usefulmore » in and of itself, but their utility is greatly enhanced by the interaction with the immunology and pharmacology components of the program.« less

  • ;
    This research continues the long term goals of promoting nuclear medicine applications by improving the scientific basis for tumor diagnosis, treatment and treatment follow-up based on the use of cyclotron produced radiotracers in oncology. This program fits into the nuclear medicine component of DOE`s mission, which is aimed at enhancing the beneficial applications of radiation, radionuclides, and stable isotopes in the diagnosis, study and treatment of human diseases. The grant includes 3 interactive components: Radiochemistry/Cyclotron; Pharmacology/Immunology; and Imaging Physics. An essential strategy is as follows: novel radionuclides and radiotracers developed in the Radiochemistry/Section under the DOE grant during the 1992--1995more » will be employed in the Pharmacology/Immunology component in the period 1996--1999. Imaging Physics resolves relevant imaging related physics issues that arise during the experimentation that results. In addition to the basic research mission, this project also provides a basis for training of research scientists in radiochemistry, immunology, bioengineering and imaging physics.« less

  • ;
    This new DOE proposal appropriately builds on past developments. The development and application of radionuclides for diagnosis, treatment and research has been a continuing concern for more than the past three decades. A brief description of this development and previous achievements was considered important in order to provide a frame of reference for the evolving program here. Earlier, the use of certain radionuclides, radon progeny and I-131 in particular, and also x-rays, had been developed by the work of such pioneers as Failla, Quimby and Marinelli. In 1952, at the instigation of Dr. C.P. Rhoads, Director of both Memorial Hospitalmore » and Sloan-Kettering Institute, the restoration of the Department of Physics and Biophysics was undertaken in response to a perceived need to promote the utilization of radionuclides and of high energy radiations for therapeutic, diagnostic and research purposes. This resulted in several research and developmental projects with close clinical collaboration in areas of radiation treatment; medical studies with radionuclides and labeled compounds; the diagnostic uses of x-rays; and some projects in surgery and other clinical areas. Aspects of some of these projects that have had some relevance for the evolving AEC-DOE projects are outlined briefly. 34 refs.« less